MiMedx Group, Inc. (OTC PINK: MDXG) focuses on the advanced wound care market and an emerging therapeutic biologics company that offers a portfolio of products derived from human tissue for clinical use.
MiMedx is focused on advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.9 million allografts to date to help patients across a range of clinical applications including the treatment of chronic non-healing wounds, pain, and other orthopedic and reconstructive procedures. In July 2020, EW led a $100 million private investment into the public equity of MiMedx. Concurrently, the Company also raised $50 million in debt to further strengthen its balance sheet and support the Company’s strategic vision going forward.